Harmony Biosciences (HRMY) Tops Q2 EPS by 20c ; Offers Guidance

Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.92, $0.20 better than the analyst estimate of $0.72. Revenue for the quarter came in at $200.5 million versus the consensus estimate of $204.59 million.

GUIDANCE:

Harmony Biosciences sees FY2025 revenue of $820-860 million, versus the consensus of $843.6 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• MSC Industrial (MSM) Tops Q3 EPS by 17c, Beats on Revenue
• ConnectOne Bancorp (CNOB) Removed from Raymond James Analyst Current Favorites list
• RPM International (RPM) Declares $0.54 Quarterly Dividend; 1.9% Yield